Table 1.
Demographic and clinical characteristics of study subjects.
| Elite controllers | ART+ treated | Viremic | Healthy controls | |
|---|---|---|---|---|
| Patients, n | 19 | 19 | 8 | 17 |
| Age, years, median (range) | 46 (28–68) | 52 (40–68) | 33 (24–71) | 49 (27–65) |
| Male, n (%) | 10 (53) | 16 (84) | 4 (50) | 9 (53) |
| Ethnicity, n (%) | ||||
| Caucasian | 8 (42) | 14 (73.5) | 5 (62.5) | 16 (94) |
| Black | 10 (53) | 4 (21) | 3 (37.5) | 0 (0) |
| Other | 1 (5) | 1 (5.5) | 0 (0) | 1 (6) |
| Mode of transmission, n (%) | ||||
| Heterosexual | 10 (53) | 10 (52.5) | 5 (62.5) | NA |
| MSM | 4 (22) | 5 (26) | 2 (25) | NA |
| IVDU | 2 (10.5) | 3 (16) | 0 (0) | NA |
| Blood products | 2 (10.5) | 1 (5.5) | 0 (0) | NA |
| Unknown | 1 (5) | 0 (0) | 1 (12.5) | NA |
| Years since diagnosis, median (min–max) | 9 (2.7–32.8) | 20 (13–31) | 0 (0–1.5) | NA |
| HIV subtype, n (%) | ||||
| B | 2 (10.5) | 2 (10.5) | 4 (50) | NA |
| C | 5 (26) | 1 (5.5) | 1 (12.5) | NA |
| CRF | 2 (10.5) | 1 (5.5) | 2 (25) | NA |
| Other or ND | 10 (53) | 15 (78.5) | 1 (12.5) | NA |
| Clinical parameters at time of sampling, median (min–max) | ||||
| CD4+ T-cell count (cells/μl) | 950 (480–1,655) | 550 (360–1,160) | 418.5 (157–700) | NA |
| CD4+ T-cell % | 46 (21–60) | 34 (21–57) | 27.5 (7–43) | NA |
| CD8+ T-cell count (cells/μl) | 780 (505–2,055) | 580 (230–1,270) | 823.5 (300–1,572) | NA |
| CD8+ T-cell % | 32.5 (22–64) | 39 (19–55) | 47 (31–68.5) | NA |
| CD4+/CD8+ ratio | 1.475 (0.33–2.79) | 0.9 (04–3) | 1.475 (0.33–2.79) | NA |
| HIV RNA (copies/ml) | <19 (19–225) | <19 (19–19) | 7,697 (1,897–55,088) | NA |
MSM, men who have sex with men; IVDU, intravenous drug use; ND, not determined; NA, not available.